We are focused on developing important new therapies that provide meaningful benefit to patients.

Dermira is committed to identifying the unmet needs of patients living with chronic skin conditions and harnessing scientific advances to develop differentiated, novel therapies that address the needs of these patients.

With our deep insight in skin biology and our thorough understanding of unmet patient needs, we are developing a portfolio of unique therapies to elevate the standard of care for patients living with skin conditions.

Our robust and growing product pipeline includes three late-stage product candidates:

  • Research
  • Preclin
  • Phase Ph1
  • Ph2
  • Ph3
Glycopyrronium Tosylate Topical anticholinergic for primary axillary hyperhidrosis
  • Ph3
(certolizumab pegol)
Injectible TNF inhibitor for plaque psoriasis
  • Ph3
Olumacostat Glasaretil Topical ACC inhibitor that targets sebum for acne vulgaris
  • Ph3
Early Research Programs Undisclosed targets
  • Res.